Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects

BACKGROUND: KM-023 is a new second-generation nonnucleoside reverse-transcriptase inhibitor that is under development for the treatment of human immunodeficiency virus (HIV) type 1 infection. OBJECTIVE: This study determined KM-023 tolerability and pharmacokinetic characteristics in healthy subjects...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Cha, Yu-Jung, Lim, Kyoung Soo, Park, Min-Kyu, Schneider, Stephen, Bray, Brian, Kang, Myung-Chol, Chung, Jae-Yong, Yoon, Seo Hyun, Cho, Joo-Youn, Yu, Kyung-Sang
Formato: Artigo
Idioma:Inglês
Publicado: Dove Medical Press 2014
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4189701/
https://ncbi.nlm.nih.gov/pubmed/25302016
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S65596
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares